Pazopanib: an antiangiogenic drug in perspective

被引:16
作者
Castaneda, Carlos A. [1 ]
Gomez, Henry L. [1 ]
机构
[1] Inst Nacl Enfermedades Neoplas, Div Med, Lima, Peru
关键词
angiogenesis; breast; cervix; glyomas; lung; multiple myeloma; ovarian; pazopanib; renal; sarcomas; thyroid; tyrosine kinase; VEGF; ENDOTHELIAL-GROWTH-FACTOR; RENAL-CELL CARCINOMA; MULTIKINASE ANGIOGENESIS INHIBITOR; METASTATIC COLORECTAL-CANCER; BEVACIZUMAB PLUS IRINOTECAN; FACTOR VEGF OVEREXPRESSION; TYROSINE KINASE INHIBITOR; SOFT-TISSUE SARCOMA; PHASE-II; MULTIPLE-MYELOMA;
D O I
10.2217/FON.09.112
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pazopanib, a tyrosine kinase inhibitor targeted to angiogenesis, has been tested in preclinical and clinical trials and has shown promising activity against a variety of solid tumors, such as renal cancer, all of which are related to the angiogenic pathway, It has a safety profile related to this mechanism of action. Diarrhea, hypertension, hair depigmentation and nausea are the most common side effects. Pazopanib is currently under evaluation as monotherapy and in combination with some potentially synergistic agents of proven activity.
引用
收藏
页码:1335 / 1348
页数:14
相关论文
共 84 条
[81]   Vascular changes in hepatocellular carcinoma [J].
Yang, Zhen Fan ;
Poon, Ronnie T. P. .
ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY BIOLOGY, 2008, 291 (06) :721-734
[82]  
Yau CC, 2009, J CLIN ONCOL, V27
[83]   Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas [J].
Yudoh, K ;
Kanamori, N ;
Ohmori, K ;
Yasuda, T ;
Aoki, M ;
Kimura, T .
BRITISH JOURNAL OF CANCER, 2001, 84 (12) :1610-1615
[84]   Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma [J].
Zangari, M ;
Anaissie, E ;
Stopeck, A ;
Morimoto, A ;
Tan, N ;
Lancet, J ;
Cooper, M ;
Hannah, A ;
Garcia-Manero, G ;
Faderl, S ;
Kantarjian, H ;
Cherrington, J ;
Albitar, M ;
Giles, FJ .
CLINICAL CANCER RESEARCH, 2004, 10 (01) :88-95